Arbutus Biopharma Corp

ABUS • Biotechnology

$5.15

— 0.00 (0.00%)

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$1.02B

Crecimiento

-7.3%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.05Liquidez saludable · 15.73Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 14 ago 2026, 12:10 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$5.15

Change0.00%

Shares Out197.47M

Market Cap$1.02B

Enterprise Value$924.86M

52W Range3.31 - 5.38

Beta0.60

P/E6.64

P/S5.60

P/B3.93

P/FCF-41.30

EV/Sales5.09

Price$5.15

Change0.00%

Shares Out197.47M

Market Cap$1.02B

Enterprise Value$924.86M

52W Range3.31 - 5.38

Beta0.60

P/E6.64

P/S5.60

P/B3.93

P/FCF-41.30

EV/Sales5.09

EV/EBITDA6.22

EV/FCF-37.56

Earnings Yield15.05%

FCF Yield-2.42%

Dividend Yield0.00%

Gross Margin97.42%

Oper. Margin-192.08%

Profit Margin-2.38%

Debt/Eq0.05

Current Ratio15.73

Quick Ratio15.73

Revenue 5Y-7.29%

Target$8.50

Target Upside65.05%

Target Median$8.50

Target Range8.50 - 8.50

Volume1.38M

Avg Volume1.93M

EPS Surprise0.90

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

20/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.05Liquidez saludable · 15.73Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

ABUS

Analyst sentiment

Based on 10 analyst votes · 2026-09-05

90/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-14

Bajo

$8.50

Promedio

$8.50

Mediana

$8.50

Alto

$8.50

Resumen de la compañía

IPO: 7/26/2007

Industria: Biotechnology

P/B i: 3.93

Deuda / Patrimonio i: 0.05

Margen operativo: -192.08%

Margen neto: -237.88%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.05

Ratio corriente: 15.73

Ratio rápido: 15.73

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Beardsley Robert A

Transacción: 06/08/2026

COMPRA

Cambio

+78,800

Precio

$4.24

Presentación

06/10/2026

Tipo

COMPRA

Sawhney Roger

Transacción: 06/08/2026

COMPRA

Cambio

+78,800

Precio

$4.24

Presentación

06/10/2026

Tipo

COMPRA

Androski Lindsay

Transacción: 02/02/2026

COMPRA

Cambio

+28,000

Precio

Not reported

Presentación

02/02/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Beardsley Robert A	COMPRA	+78,800	$4.24	06/08/2026	06/10/2026
Sawhney Roger	COMPRA	+78,800	$4.24	06/08/2026	06/10/2026
Androski Lindsay	COMPRA	+28,000	Not reported	02/02/2026	02/02/2026
Androski Lindsay	COMPRA	+71,700	$4.39	02/02/2026	02/02/2026
Nguyen Tuan	COMPRA	+73,500	Not reported	02/02/2026	02/02/2026
Nguyen Tuan	COMPRA	+188,400	$4.39	02/02/2026	02/02/2026
Sawhney Roger	OTRO	0	Not reported	08/04/2025	08/06/2025
Sawhney Roger	COMPRA	+157,600	$3.34	08/04/2025	08/06/2025
Nguyen Tuan	COMPRA	+750,000	$3.49	03/31/2025	04/01/2025
Nguyen Tuan	COMPRA	+750,000	$3.50	03/31/2025	03/31/2025
Nguyen Tuan	OTRO	0	Not reported	03/28/2025	03/31/2025
Androski Lindsay	COMPRA	+310,422	$3.20	03/18/2025	03/20/2025
Beardsley Robert A	COMPRA	+157,600	$3.20	03/18/2025	03/20/2025
Hasija Anuj	COMPRA	+157,600	$3.20	03/18/2025	03/20/2025
Gline Matthew	OTRO	0	Not reported	02/24/2025	03/06/2025
Androski Lindsay	OTRO	0	Not reported	02/24/2025	03/06/2025
Beardsley Robert A	OTRO	0	Not reported	02/24/2025	03/06/2025
Bishop Joseph E	OTRO	0	Not reported	02/24/2025	03/06/2025
Hasija Anuj	OTRO	0	Not reported	02/24/2025	03/06/2025
Sims Karen	COMPRA	+49,300	Not reported	02/14/2025	02/19/2025

Sobre la compañía

Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Fuente - Link

Competidores

BCAX EYPT GHRS KURA NBTX PROK SEPN SPRY SVRA TNGX

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Connor Clark & Lunn Investment Management Ltd. Buys Shares of 130,023 Arbutus Biopharma Corporation $ABUS

Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Arbutus Biopharma Corporation (NASDAQ: ABUS) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 130,023 shares of the biopharmaceutical company's stock, valued at approximately $624,000. Connor Clark and Lunn Investment Management Ltd.

Defense World

Bank of America Corp DE Has $7.58 Million Stock Position in Arbutus Biopharma Corporation $ABUS

Bank of America Corp DE lowered its stake in Arbutus Biopharma Corporation (NASDAQ: ABUS) by 8.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,683,628 shares of the biopharmaceutical company's stock after selling 149,076 shares during the quarter. Bank of

Defense World

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the commencement of a modified “Dutch Auction” tender offer to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”) at a price of not less than US$5.00 and not more than US $5.75 per Share, less any applicable withholding taxes and without interest, on the terms and subject to the conditions described in the offer to purchase and accompanying issuer bid circular, dated August 24, 2026 (the “Offer to Purchase and Bid Circular”), the Letter of Transmittal (the “Letter of Transmittal”) and Notice of Guaranteed Delivery (the “Notice of Guaranteed Delivery”) (which together, as they may be amended and supplemented from time to time, constitute the “Offer”).

GlobeNewsWire

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified “Dutch Auction” tender offer (the “Offer”) to repurchase up to US$230 million of its common shares at a purchase price of not less than US$5.00 per share and not more than US$5.75 per share, in cash, less any applicable withholding taxes and without interest. The Offer is expected to commence on or about August 24, 2026 and, unless extended or terminated by the Company, expire on or about September 29, 2026. The Offer is expected to be funded through the Company's cash on hand.

GlobeNewsWire

Head-To-Head Comparison: YD Bio (NASDAQ:YDES) versus Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma (NASDAQ: ABUS - Get Free Report) and YD Bio (NASDAQ: YDES - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation. Profitability This table compares Arbutus Biopharma and

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-13	-0.03	0.87	0.9
2026-03-23	-0.03505	-0.01	0.02505
2025-11-13	-0.056	-0.04	0.016
2025-08-06	-0.02	0.01	0.03
2025-05-14	-0.09	-0.13	-0.04
2025-03-27	-0.08	-0.07	0.01
2024-11-06	-0.1	-0.1	0
2024-08-01	-0.1	-0.11	-0.01
2024-05-02	-0.1	-0.1	0
2024-02-29	-0.12	-0.12	0
2023-11-07	-0.12	-0.12	0
2023-08-03	-0.12	-0.1	0.02